Human Genome Epidemiology Literature Finder
Records 1 - 16 (of 16 Records) |
Query Trace: Body Weight and CYP2B6[original query] |
---|
Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. British journal of clinical pharmacology 2006 Feb 61 (2): 148-54. Burger David, van der Heiden Ilse, la Porte Charles, van der Ende Marchina, Groeneveld Paul, Richter Clemens, Koopmans Peter, Kroon Frank, Sprenger Herman, Lindemans Jan, Schenk Paul, van Schaik R |
Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children. Antiviral therapy 2009 14 (3): 315-20. Puthanakit Thanyawee, Tanpaiboon Pranoot, Aurpibul Linda, Cressey Tim R, Sirisanthana Vir |
Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrobial agents and chemotherapy 2009 Jul 53 (7): 2791-8. Cabrera Salvador E, Santos Dolores, Valverde María P, Domínguez-Gil Alfonso, González Francisco, Luna Guillermo, García María |
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clinical pharmacology and therapeutics 2009 May 85 (5): 485-94. Arab-Alameddine M, Di Iulio J, Buclin T, Rotger M, Lubomirov R, Cavassini M, Fayet A, Décosterd L A, Eap C B, Biollaz J, Telenti A, Csajka C, |
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. The Journal of antimicrobial chemotherapy 2011 Jun 66 (6): 1332-9. Schipani Alessandro, Wyen Christoph, Mahungu Tabitha, Hendra Heidy, Egan Deirdre, Siccardi Marco, Davies Gerry, Khoo Saye, Fätkenheuer Gerd, Youle Michael, Rockstroh Jürgen, Brockmeyer Norbert H, Johnson Margaret A, Owen Andrew, Back David J, |
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. Antimicrobial agents and chemotherapy 2012 Dec . Manosuthi W, Sukasem C, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S |
Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children. Antimicrobial agents and chemotherapy 2014 58 (1): 136-43. Salem Ahmed Hamed, Fletcher Courtney V, Brundage Richard |
CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1. Antimicrobial agents and chemotherapy 2014 58 (4): 2268-73. Manosuthi Weerawat, Sukasem Chonlaphat, Thongyen Supeda, Nilkamhang Samruay, Manosuthi Sukanya, Sungkanuparph Somnu |
CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe. BMC pharmacology & toxicology 2015 16 4. Dhoro Milcah, Zvada Simbarashe, Ngara Bernard, Nhachi Charles, Kadzirange Gerald, Chonzi Prosper, Masimirembwa Coll |
Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain. Fundamental & clinical pharmacology 2016 Apr 30 (2): 153-61. de Moraes Natália V, Lauretti Gabriela R, Coelho Eduardo B, Godoy Ana Leonor P C, Neves Daniel V, Lanchote Vera |
Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin. PloS one 2017 9 12 (9): e0181316. Soeria-Atmadja Sandra, Österberg Emma, Gustafsson Lars L, Dahl Marja-Liisa, Eriksen Jaran, Rubin Johanna, Navér La |
Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients. Antimicrobial agents and chemotherapy 2017 May . Habtewold Abiy, Aklillu Eleni, Makonnen Eyasu, Yimer Getnet, Bertilsson Leif, Burhenne Jürgen, Owen Joel |
Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz. Pharmacogenetics and genomics 2020 Mar . Adegbola Adebanjo Jonathan, Rana Abutaima, Adeagbo Babatunde Ayodeji, Bolarinwa Rahman A, Olagunju Adeniyi Ebenezer, Siccardi Marco, Owen Andrew, Bolaji Oluseye Oladot |
Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer. Clinical pharmacology and therapeutics 2020 Oct . Puszkiel Alicja, Arellano Cécile, Vachoux Christelle, Evrard Alexandre, Le Morvan Valérie, Boyer Jean-Christophe, Robert Jacques, Delmas Caroline, Dalenc Florence, Debled Marc, Venat-Bouvet Laurence, Jacot William, Dohollou Nadine, Bernard-Marty Chantal, Laharie-Mineur Hortense, Filleron Thomas, Roché Henri, Chatelut Etienne, Thomas Fabienne, White-Koning Melan |
Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population. Pharmaceuticals (Basel, Switzerland) 2021 4 14 (3): . Barnett Shelby, Errington Julie, Sludden Julieann, Jamieson David, Poinsignon Vianney, Paci Angelo, Veal Gareth |
Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021 12 75 (3): 399-405. van Rensburg Roland, Nightingale Sam, Brey Naeem, Albertyn Christine H, Kellermann Tracy A, Taljaard Jantjie J, Esterhuizen Tonya M, Sinxadi Phumla Z, Decloedt Eric |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source: